Report cover image

Growth Hormone Deficiency Market - A Global and Regional Analysis: Focus on Treatment Type, ROA, Distribution Channel, Country, and Region - Analysis and Forecast, 2025-2035

Publisher BIS Research
Published Jan 06, 2026
SKU # BIS20695558

Description

Global Growth Hormone Deficiency Market, Analysis and Forecast: 2025-2035

The Growth Hormone Deficiency (GHD) market revolves around the treatment and management of a condition where the pituitary gland does not produce enough growth hormone. This condition affects both children and adults and can lead to significant health challenges, including stunted growth in children and metabolic, cardiovascular, and psychological issues in adults.

Several emerging trends are shaping the future of the GHD market. One significant trend is the shift towards long acting growth hormone formulations, which are becoming increasingly popular in both paediatric and adult GHD treatments. Traditional therapies required daily injections, but new long acting formulations, which are administered less frequently (e.g., once weekly), are gaining traction due to their convenience and potential to improve patient adherence. These formulations are expected to dominate the market by 2030, especially in developed regions like the U.S., Germany, and Japan. Another notable trend is the increasing focus on adult onset GHD, a patient population that remains largely underserved. With more recognition of the metabolic and psychological impacts of untreated GHD in adults, there is a growing emphasis on diagnosing and treating this condition in older patients.

Furthermore, the market is seeing advances in diagnostic tools and treatment delivery mechanisms. For instance, auto injectors and digital health monitoring tools are making it easier for patients to adhere to therapy, and these innovations are helping to improve the overall treatment experience. As the treatment options become more personalized, with tailored doses and optimized delivery systems, patients are experiencing better outcomes, which further propels the market forward.

There are several opportunities in the GHD market. The largest opportunity lies in untapped patient populations, especially adults who remain undiagnosed. As awareness and understanding of adult‑onset GHD grow, the number of diagnosed patients is likely to increase. There is also significant growth potential in emerging markets like Asia‑Pacific and Latin America, where healthcare access and awareness are improving, but treatment uptake remains lower than in North America and Europe. These regions represent blue‑ocean opportunities for companies looking to expand their market share.

The regional outlook for the GHD market shows strong dominance by North America and Europe, where the market is well-established and therapies are widely accessible. However, growth in these regions is expected to slow due to market maturity. In contrast, Asia Pacific is expected to be the fastest-growing region due to improving healthcare infrastructure, increasing awareness of GHD, and rising healthcare expenditures. Countries like China and India represent significant potential, although challenges such as cost barriers, access to care, and physician awareness remains. The synthetic hormone is being used for treating Growth Hormone Deficiency (GHD) which has seen significant growth in recent years, driven by advancements in recombinant DNA technology, which allows for the production of high-quality synthetic growth hormones. These synthetic hormones, designed to mimic natural growth hormone, are increasingly used in both pediatric and adult populations, offering a viable treatment option for individuals with GHD. The growing awareness of GHD, along with innovations in drug delivery systems, has further accelerated the demand for synthetic hormones in global healthcare markets.

The competitive landscape of the GHD market is dominated by several major pharmaceutical companies that produce recombinant human growth hormones (rhGH) and related products. Leading players include Novo Nordisk, Pfizer, Eli Lilly, Ipsen, and Ferring Pharmaceuticals, each offering a variety of GHD therapies in different formats (daily vs. long acting). Novo Nordisk, for instance, is a leader in the GHD space with its Norditropin brand and its long acting growth hormone formulations. These players are facing pressure from emerging biotech companies and the increasing presence of biosimilars, which may drive down prices and increase competition.

Market Segmentation:

Segmentation 1: by Treatment Type

Recombinant Human Growth Hormone Therapies
Long-acting Growth Hormone Therapies
Human‑pituitary Derived Extracts

Segmentation 2: by ROA

Subcutaneous Injection
Intramuscular Injection
Long-acting Injectables

Segmentation 3: by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Segmentation 4: by Region

North America
Europe
Asia-Pacific
Rest-of-the-World

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Table of Contents

Executive Summary
Scope of the Study
1. Global Growth Hormone Deficiency Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Growth Hormone Deficiency Profile
1.3 Epidemiological Analysis of Growth Hormone Deficiency Market
1.3.1 Prevalence and Incidence of Bleeding Disorders
1.3.2 Geographic Distribution
1.3.3 Age and Gender Distribution
1.3.4 Impact on Healthcare System
1.4 Market Trends
1.5 Growth Share Analysis by Company
1.6 Regulatory Landscape Analysis
1.6.1 Legal Requirement and Framework in U.S.
1.6.2 Legal Requirement and Framework in E.U.
1.6.3 Legal Requirement and Framework in Asia-Pacific
1.6.4 Legal Requirement and Framework in Rest-of-the-World
1.7 Market Dynamics
1.7.1 Impact Analysis
1.7.2 Market Drivers
1.7.3 Market Restraints
1.7.4 Market Opportunities
2. Global Growth Hormone Deficiency Market, (by Treatment Type), $Million, 2024-2035
2.1 Overview
2.2 Recombinant Human Growth Hormone Therapies
2.3 Long-acting Growth Hormone Therapies
2.4 Human‑pituitary Derived Extracts
3. Global Growth Hormone Deficiency Market, (by ROA), $Million, 2024-2035
3.1 Overview
3.2 Subcutaneous Injection
3.3 Intramuscular Injection
3.4 Long-acting Injectables
4. Global Growth Hormone Deficiency Market, (by Distribution Channel), $Million, 2024-2035
4.1 Overview
4.2 Hospital Pharmacies
4.3 Retail Pharmacies
4.4 Online Pharmacies
5. Global Growth Hormone Deficiency Market, (by Region), $Million, 2024-2035
5.1 North America
5.1.1 Key Findings
5.1.2 Market Dynamics
5.1.3 Market Sizing and Forecast
5.1.3.1 North America Growth Hormone Deficiency Market (by Country)
5.1.3.1.1 U.S.
5.1.3.1.2 Canada
5.2 Europe
5.2.1 Key Findings
5.2.2 Market Dynamics
5.2.3 Market Sizing and Forecast
5.2.3.1 Europe Growth Hormone Deficiency Market (by Country)
5.2.3.1.1 Germany
5.2.3.1.2 France
5.2.3.1.3 Italy
5.2.3.1.4 Spain
5.2.3.1.5 U.K.
5.2.3.1.6 Rest-of-Europe
5.3 Asia-Pacific
5.3.1 Key Findings
5.3.2 Market Dynamics
5.3.3 Market Sizing and Forecast
5.3.3.1 Asia-Pacific Growth Hormone Deficiency Market (by Country)
5.3.3.1.1 Japan
5.3.3.1.2 China
5.3.3.1.3 Rest-of-Asia-Pacific
5.4 Rest-of-the-World
5.4.1 Key Findings
5.4.2 Market Dynamics
5.4.3 Market Sizing and Forecast
6. Competitive Benchmarking and Company Profiles
6.1 Competitive Benchmarking
6.2 Competitive Landscape
6.2.1 Key Strategies and Developments by Company
6.2.1.1 Funding Activities
6.2.1.2 Mergers and Acquisitions
6.2.1.3 Regulatory Approvals
6.2.1.4 Partnerships, Collaborations, and Business Expansions
6.2.2 Key Developments Analysis
6.3 Company Profiles
6.3.1 Novo Nordisk A/S
6.3.1.1 Company Overview
6.3.1.2 Product Portfolio
6.3.1.3 Target Customers/End Users
6.3.1.4 Key Personnel
6.3.1.5 Analyst View
6.3.2 Eli Lily and Company
6.3.2.1 Company Overview
6.3.2.2 Product Portfolio
6.3.2.3 Target Customers/End Users
6.3.2.4 Key Personnel
6.3.2.5 Analyst View
6.3.3 Pfizer, Inc.
6.3.3.1 Company Overview
6.3.3.2 Product Portfolio
6.3.3.3 Target Customers/End Users
6.3.3.4 Key Personnel
6.3.3.5 Analyst View
6.3.4 Merck KGaA
6.3.4.1 Company Overview
6.3.4.2 Product Portfolio
6.3.4.3 Target Customers/End Users
6.3.4.4 Key Personnel
6.3.4.5 Analyst View
6.3.5 Ispen SA
6.3.5.1 Company Overview
6.3.5.2 Product Portfolio
6.3.5.3 Target Customers/End Users
6.3.5.4 Key Personnel
6.3.5.5 Analyst View
7. Research Methodology
List of Figures
Figure: Growth Hormone Deficiency Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Growth Hormone Deficiency Market, 2024 and 2035
Figure: Global Growth Hormone Deficiency Market Key Trends, Impact Analysis, 2024-2035
Figure: North America Growth Hormone Deficiency Market, $Million, 2024-2035
Figure: Europe Growth Hormone Deficiency Market, $Million, 2024-2035
Figure: Asia-Pacific Growth Hormone Deficiency Market, $Million, 2024-2035
Figure: Rest-of-the-World Growth Hormone Deficiency Market, $Million, 2024-2035
List of Tables
Table: Market Snapshot
Table: Market Dynamics
Table: Global Growth Hormone Deficiency Market (by Treatment Type), $Million, 2024-2035
Table: Global Growth Hormone Deficiency Market (by ROA), $Million, 2024-2035
Table: Global Growth Hormone Deficiency Market (by Distribution Channel), $Million, 2024-2035
Table: Global Growth Hormone Deficiency Market (by Region), $Million, 2024-2035

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us